Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 291Carcinoma, Renal Cell 172Kidney Neoplasms 118Urinary Bladder Neoplasms 102Breast Neoplasms 70Neoplasms 64Melanoma 48Testicular Neoplasms 45Sarcoma 45Wilms Tumor 44Lung Neoplasms 42Ovarian Neoplasms 41Neuroblastoma 39Colonic Neoplasms 34Lymphoma, Non-Hodgkin 32Lymphoma 31Osteosarcoma 28Neoplasm Metastasis 28Carcinoma, Non-Small-Cell Lung 28Pancreatic Neoplasms 26Neuroectodermal Tumors, Primitive, Peripheral 25Uterine Cervical Neoplasms 24Colorectal Neoplasms 23Carcinoma, Transitional Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Medulloblastoma 22Urethral Neoplasms 21Central Nervous System Neoplasms 21Carcinoma, Ovarian Epithelial 21Burkitt Lymphoma 21

Interventions

berzosertib 1Platinum 1Gemcitabine 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Metastatic Bladder Urothelial Carcinoma × Genitourinary × Clear all
NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled 13 charts
Genitourinary

Metastatic Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡